Menovar (603538.SH) subsidiary atorvastatin calcium raw materials passed CDE technical review

Zhitongcaijing · 2d ago

Zhitong Finance App News, Minova (603538.SH) issued an announcement. Recently, Xuancheng Minova Pharmaceutical Co., Ltd. (“Xuancheng Minova”), the company's holding subsidiary, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for atorvastatin calcium raw materials approved and issued by the China Drug Administration.

Xuancheng Menova's atorvastatin calcium API passed the CDE technical review, proving that the API has met relevant national drug evaluation technical standards and can be sold to the domestic market. It will further enrich the subsidiary's product line, help expand the company's business area, further expand the company's integrated production scope of API formulations, and enhance the company's integrated production advantages.